Pharmaceutical Raw Material Lapatinib CAS 231277-92-2 for Breast Cancer

Model: HKYC
Place of Origin: Hubei,China (Mainland)
package: Special disguised packaging or as your demand
service: resend guarantee
Payment Terms: Western Union, MoneyGram, Bank transfer, Bitcoin
Supply Ability: Mass Stock
Certification: ISO
Model Number: 231277-92-2 f
Active-Life: 7-9 days
Usage: Pharmaceutical Raw
Lead Time: Within 12 Hours After Payment Confirmed
Shipping: 3-7 Days / Door-to-Door

inquiry

skype basketAdd to Basket  Edit

Share |

Product Description

Payment & Shipping Terms Supply Capacity
Unit Price:160.0~290.0 USDProduction Capacity:100000L/WEEK
Payment Terms:T/T, WU, Money Gram, bitcoinPacking:brand new
Min. Order:100 mlDelivery Date:with 6 working hours
Means of Transport:Air




  • CAS No.: 388082-78-8

  • Other Names: Lapatinib ditosylate hydrate

  • MF: C41H40ClFN4O11S3

  • EINECS No.: 388082-78-8

  • Place of Origin: Shanghai, China (Mainland)

  • Type: Antineoplastic Agents

  • Grade Standard: Medicine Grade

  • Usage: Animal Pharmaceuticals

  • Brand Name:TwoChem

  • Purity: 99%

  • Appearance: White Powder

  • Application: API Used for the treatment of breast cancer.

The COA of this product :

ITEMSSPECIFICATIONTESTRESULTS
AppearanceOff-white or white powderConforms
IdentificationHPLC,NMR;LC-MSConforms
Related substancesIndividual impurity≤0.5%0.09%
Total impurities≤1.0%0.20%
Loss on drying≤0.5%0.3%
Residue on ignition≤0.1%0.04%
Heavy metals≤10ppmConforms
Assay≥98.0 %99.1%

Description:

Lapatinib (INN), used in the form of lapatinib ditosylate, (USAN) (Tykerb/Tyverb, GSK) is an orally active drug for breast cancer and other solid tumours. It is a dual tyrosine kinase inhibitor which interrupts the HER2/neu and epidermal receptor (EGFR) pathways.

It is used in combination therapy for HER2-positive breast cancer. It is used for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress HER2 (ErbB2).
 


Usage:

1) Lapatinib is a breast cancer targeted therapy drug . Breast cancer molecular targeted therapy aims at the occurrence and development of cancer-related genes and their expression products of breast cancer for treatment. Molecular targeted drug by blocking signal transduction of tumor cells or associated cells , control changes in cell gene expression, in order to inhibit or kill tumor cells.

 

2) Lapatinib is a novel targeted anti-cancer drug. It Can act on Her-1 and Her-2 two targets at he same time, the biological effect of the inhibition of tumor cell proliferation and growth arising from this mode of action is much larger than acting on just one target. The so-called targeted therapy, refers to certain receptors, genes or proteins as a key target, and then targets to kill tumor cells related to drug.


Lapatinib ditosylate COA

TEST ITEMSSPECIFICATIONRESULTS
DescriptionLight yellow or almost white crystalline powderLight Yellow powder
IdentificationIRPositive
Assay97.0~103.0%99.37%
Melting Point70~80°C70.5~76.5°C
Specific Rotation+22~+26°+23.09°
Loss On Drying0.5%max0.25%
Residue On Ignition0.1%max0.05%
Heavy Metals20PPm max<20PPm
Organic Volatile ImpuritiesMeets the requirement.Conforms

Related Substances
Single Impurity: 1.0%max<1.0%
Total Impurities: 2.0%max<2.0%
ConclusionThe specification conforms to enterprise standard.


Category: Other pharmaceuticals

Related Category: antibiotics